KA-2720 / Grifols, TuHURA Bio - LARVOL DELTA

CD27 is a new promising T cell co-stimulatory target for the cancer immunotherapy – development and selection of a lead anti-CD27 agonist antibody (SITC 2023) - "It also demonstrated a significant antitumor effect as a single agent in human CD27-Knockin mice (hCD27-KI) subcutaneously implanted with MC38 or in NOD-SCID mice subcutaneously implanted with Raji. Conclusions These preclinical results establish that the selected anti-CD27 mAb is a promising drug candidate and we are actively pursuing its development."

IO biomarker • Oncology • CD27 • CD4 • CD69 • CD70 • CD8 • IFNG • TNFA

Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (GlobeNewswire) - "Kineta...announced today the presentation of new preclinical data on the company’s anti-CD27 agonist monoclonal antibodies (mAbs) at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting....Kineta’s selected lead anti-CD27 candidate demonstrated antitumor efficacy in vivo as a single agent and in combination with other immunotherapies in multiple solid and hematological mouse tumor models."

Preclinical • Hematological Malignancies • Solid Tumor

Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy (GlobeNewswire) - "Kineta, Inc....announced today that it will present a poster on the Company’s anti-CD27 agonist antibody program at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, to be held on October 1-4, 2023 in Toronto, ON, Canada. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting new preclinical data on the company’s anti-CD27 agonist antibodies in development for the treatment of advanced solid tumors."

Preclinical • Oncology • Solid Tumor

Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy (GlobeNewswire) - "Kineta...announced today the presentation of new preclinical data on the company’s anti-CD27 agonist monoclonal antibodies (mAbs) in development for the treatment of advanced solid tumors at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy....Strong agonist proprieties on T cell proliferation and activation after engagement of NFkB-mediated CD27 signaling as well as NK cell activation were also observed. Importantly, the nominated lead mAb showed antitumor efficacy in vivo in solid and hematological mouse tumor models as a single agent or in combination with other immunotherapies."

Preclinical • Hematological Malignancies • Solid Tumor

Kineta Completes Reverse Merger with Yumanity Therapeutics (GlobeNewswire) - "Kineta, Inc...announced today the completion of its reverse merger with Yumanity Therapeutics, Inc. ('Yumanity')....Kineta plans to execute on its clinical development program to unlock the potential of KVA12123....A Phase 1 / Phase 2 clinical trial evaluating KVA12123 alone and in combination with pembrolizumab in patients with advanced solid tumors will begin enrolling patients in January 2023. Additionally, the Company is advancing an anti-CD27 agonist immunotherapy to address the problem of exhausted T cells and is planning to submit an Investigational New Drug application (IND) in the first half of 2024."

IND • M&A • New P1/2 trial • Oncology • Solid Tumor

CD27 an emerging immuno-oncology target at the cross-roads of innate and adaptive anti-tumor immune responses (SITC 2022) - "Previous studies have demonstrated tumor growth inhibition with anti-CD27 agonistic monoclonal antibodies in different mice models for solid and hematological tumors...Preliminary experiments performed in human CD27 KI mice have demonstrated a long half-life of our antibody at different concentrations. Conclusions Epitope characterization, NHP pharmacokinetic analysis and additional in vivo studies of our lead anti-CD27 antibody in different tumor models use as a single agent and in combination with different check-point inhibitors are on-going."

IO biomarker • Hematological Malignancies • Oncology • Solid Tumor • Thymoma • Thymus Cancer • CD27 • CD4 • CD69 • CD70 • CD8 • IFNG

Kineta to Present Pre-clinical Data on VISTA and CD27 Programs at SITC 2022 Annual Meeting (GlobeNewswire) - "Kineta, Inc...announced today that two abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held November 8-12, 2022 onsite in Boston, MA and online....Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, will highlight developmental progress of two of the Company’s novel immuno-oncology antibody therapeutics. The poster presentations will provide an overview of KVA12123 (formerly referred to as KVA12.1), Kineta’s IND-ready VISTA blocking immunotherapy for the treatment of cancer patients with advanced solid tumors that is scheduled to initiate a Phase 1 clinical trial in the fourth quarter of 2022, and the anti-CD27 agonist antibody lead candidate in development for the treatment of advanced solid tumors."

New P1 trial • Preclinical • Oncology • Solid Tumor

Kineta to Present Anti-CD27 Agonist Preclinical Program at AACR Conference on Tumor Immunology and Immunotherapy (GlobeNewswire) - "Kineta, Inc...announced today that it will present a poster on the Company’s anti-CD27 agonist antibody program at the American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy, to be held on October 21-24, 2022 as an in-person event in Boston, Massachusetts. Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, will be presenting new preclinical data on the company’s anti-CD27 agonist antibodies in development for the treatment of advanced solid tumors."

Preclinical • Oncology • Solid Tumor

Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022 (PRNewswire) - "Kineta...announced today the presentation of preclinical data on the company's anti-CD27 agonist lead antibodies at the American Association for Cancer Research (AACR) Annual Meeting 2022....Confirmed lead antibodies' binding potency and cross-reactivity with non-human primate CD27 but not with the murine CD27. Lead candidates demonstrate strong agonist proprieties....Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in Q2 2022."

Pipeline update • Preclinical • Hematological Malignancies • Oncology • Solid Tumor

Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022 (PRNewswire) - "Kineta, Inc...announced today that it will present a poster on the company's anti-CD27 agonist antibody program at the American Association for Cancer Research Annual Meeting 2022, taking place April 8-13, 2022 onsite in New Orleans, LA and online. Thierry Guillaudeux, PhD, EVP Research and Development at Kineta, will be presenting new preclinical data on the company's anti-CD27 agonist antibodies in development for the treatment of blood cancers and solid tumors."

Preclinical • Hematological Malignancies • Oncology • Solid Tumor

Kineta Presented New Preclinical Data on its Anti-CD27 Agonist Antibody Program at the ESMO Immuno-oncology Congress 2021 (PRNewswire) - "Key results from the ESMO poster presentation:...Evaluated 15 leads out of 147 fully human anti-CD27 monoclonal antibodies with unique sequences; Human T cell activation assay showed strong increased in proliferation and cytokine secretion for 3 mAbs; Surrogate in vivo model with anti-mouse CD27 agonist showed significant anti-tumor response; Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in Q1-Q2 2022."

Clinical • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor

Kineta Presents Preclinical Data on Its New CD27 Program at the AACR Conference on Tumor Immunology and Immunotherapy (PRNewswire) - “Key results from the AACR poster presentation include the following: 147 fully human monoclonal anti-CD27 antibodies with unique sequences were generated. Kineta's anti-CD27 antibodies are highly specific and cross-react with cyno-CD27. Anti-CD27 agonist assay showed particularly strong induction for eight of the anti-CD27 antibodies. Human peripheral blood T cell activation assay showed increased proliferation and cytokine secretion…‘We are currently in lead selection and will nominate a clinical candidate to advance into IND-enabling studies in 2022.’”

Preclinical • Oncology

Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy (PRNewswire) - "Kineta, Inc...announced...that it will present a poster on the company's new anti-CD27 agonist antibody program at the American Association for Cancer Research (AACR) Virtual Special Conference: Tumor Immunology and Immunotherapy, to be held on October 5-6, 2021."

Clinical • Oncology